
GenMark Diagnostics, Inc. GNMK
GenMark Diagnostics, Inc. Deferred Revenue 2011-2025 | GNMK
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue GenMark Diagnostics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 508 K | 323 K | 245 K | 448 K | 658 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 658 K | 245 K | 436 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
24.3 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.82 | -1.04 % | $ 132 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 307.08 | -0.33 % | $ 8.66 B | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 45.69 | 1.24 % | $ 6.81 K | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Boston Scientific Corporation
BSX
|
306 M | $ 91.95 | -0.67 % | $ 135 B | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 3.18 | 10.56 % | $ 119 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 9.58 | -2.84 % | $ 688 M | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 14.35 | -1.1 % | $ 1.14 B | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 0.99 | 7.52 % | $ 16 M | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 96.99 | 0.79 % | $ 1.23 B | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
1.33 B | $ 163.04 | -1.44 % | $ 12.2 B | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 1.04 | -2.06 % | $ 107 M | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 12.5 | -1.66 % | $ 338 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 14.9 | 0.99 % | $ 97.7 M | ||
|
AxoGen
AXGN
|
14 K | $ 30.0 | -1.3 % | $ 1.33 B | ||
|
LivaNova PLC
LIVN
|
10.8 M | $ 63.28 | 0.84 % | $ 3.43 B | ||
|
Globus Medical
GMED
|
22.1 M | $ 86.73 | 0.05 % | $ 11.8 B | ||
|
LENSAR
LNSR
|
1.68 M | $ 11.51 | -0.04 % | $ 133 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 13.51 | 0.67 % | $ 1.04 B | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Alphatec Holdings
ATEC
|
10.5 M | $ 19.79 | -0.85 % | $ 2.83 B | ||
|
Aethlon Medical
AEMD
|
345 K | $ 3.07 | -9.71 % | $ 4.79 M | ||
|
Establishment Labs Holdings
ESTA
|
1.75 M | $ 72.39 | -0.17 % | $ 2.04 B |